| Ytd | -34.40% | |
| 1y | -34.40% |
| Open | 9.81 | Prev Close | 9.91 | Low | 9.49 | High | 10.10 | Mkt Cap | 29.24M |
| Vol | 137.81K | Avg Vol | 360.21K | EPS | -29.46 | P/E | -0.34 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 10.46 | 200-d Avg | 11.33 | 1yr Est | 0.00 |
EIKN News
Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRi
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursda
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical co
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the
Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a ro
MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollm
Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data wi
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex
MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”)
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Comp
EIKN (NASDAQ: EIKN - Get Free Report) has received an average rating of "Moderate Buy" from the seve
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop H
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq deb
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initia
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2
Eikon Therapeutics, Inc. is pursuing an IPO to fund its oncology pipeline, led by EIK1001 in Phase 2
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering